Investment
Features
FeesSafety
Academy
More
Pluang+

Performance Food Group stock dips 5.8% despite strong growth and positive 2027 outlook

Company Fundamentals
13 Aug 2026
Seeking Alpha
View Source
Neutral
pluang ai news

Performance Food Group (PFGC) shares fell 5.8% after reporting Q4 2026 results that missed expectations, but the company showed strong year-over-year revenue and profit growth driven by its Foodservice and Convenience segments. Acquisitions and organic growth helped boost performance, although the Specialty segment faced margin challenges. Management projects 2027 revenue between $72.5 billion and $73 billion, with normalized EBITDA around $2.13 billion, expecting further growth by 2028. The stock is considered reasonably valued with potential 15–15.8% annualized upside if 2028 targets are met, maintaining a 'buy' rating.

More News

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
39 minutes ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
50 minutes ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
1 hour ago
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...

Market News
Bullish
1 hour ago
TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App